Reduced BRCA1 gene expression is common in the sporadic form of ovarian carcinoma. 3
Introduction 1
Epithelial ovarian carcinoma is the leading cause of death due to gynecological 2 malignancy (1). The great majority of these deaths occur in women who present with high grade 3 serous subtype tumors that metastasize by spreading transperitoneally through the 4 abdominopelvic cavity. High grade serous subtype tumors are also notable because they also 5 have the highest rate of BRCA1 abnormalities, a considerable proportion of which occur due to 6 epigenetic silencing rather than mutation (2). Given BRCA1's myriad roles in acting to maintain 7 genomic stability and differentiation, determining how its expression is silenced during the 8 development of high grade ovarian tumors is an important goal. 9 BRCA1 expression is tightly regulated through its promoter which is located within a 218 10 bp intragenic region between the bi-directionally controlled BRCA1 and NBR2 genes (3). A 11 strong positive regulatory region (PRR), which consists of two sub-regions, lies within a 56 bp 12 sequence from nucleotide -204 to -148 relative to the BRCA1 start site (4,5). The first upstream 13 sub-region in the PRR is the 'RIBS' element (-204 nt to -182 nt) which binds to, and is activated 14 by, a complex of GABPα and GABPß transcription factors of the ETS family (6). The second 15 sub-region is the CRE element located just downstream (-174 nt to -167 nt) which binds to, and 16 is activated by, a complex of c-Jun and Fra2 transcription factors of the AP1 complex (3,7). To 17 date, the transcriptional regulation of the BRCA1 promoter has been most thoroughly 18 characterized in breast carcinoma cells (8). However, we have demonstrated that the CRE 19 element is active in ovarian carcinoma cells (3). 20
It has long been assumed that ovarian carcinomas arise within the ovarian surface 21 epithelium (OSE; Ref. 9). However, recent findings suggest that some ovarian carcinomas may 22 arise in extraovarian tissues (10). In the case of high grade serous subtype tumors specifically, 23
there is now considerable evidence that these lesions often arise in lining epithelium of the distal 24 Zhou et al.
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portion of the fallopian tubes which is very closely related, developmentally, to the OSE (11). 1
The fallopian tube origin of high grade serous tumors has many implications for clinical 2 management, including changes to surgical intervention protocols for women who are BRCA1 3 mutation carriers who choose prophylactic early lesion removal prior to frank tumor diagnosis 4 (12) . Additionally, it indicates that the cells of frank high grade serous tumors have likely 5 already been shed into the fluid of the peritoneal cavity and then later attach to either to the 6 ovarian surface or the abdominopelvic wall where they are most often first discovered (13). 7
Given that altered interactions with extracellular matrix substrata have been shown to alter 8 BRCA1 expression in mammary epithelial cells (14,15), we reasoned that detaching pre-9 malignant ovarian cells from the substratum, in an effort to mimic their initial shedding and 10 floating in the peritoneal fluid, might also affect BRCA1 expression. 11
Pre-malignant, immortal human OSE cells were cultured either as attached, flat 12 monolayers or as detached cell clusters in suspension. Under the latter conditions steady-state 13 BRCA1 mRNA and protein levels were significantly reduced. Furthermore, the transcriptional 14 activity of the BRCA1 promoter was suppressed in suspension and this suppression was 15 mediated, at least in part, by the decreased expression of c-Jun and Fra2, both of which bind to 16 the CRE element within the promoter. This suggests that the microenvironmental loss of cell-17 subtratum adhesion that occurs during the earliest stages of transperitoneal spread may help 18 facilitate the decrease in endogenous BRCA1 expression that has been noted in a signficant 19 
Materials and Methods 1

Cell culture 2
Extended lifespan human ovarian surface epithelial IOSE-80 cells which have escaped 3 normal growth controls were generated by stable transfection with SV40 virus large T antigen in 4 the laboratory of Nelly Auersperg (Women's Hospital, Vancouver, Canada) as previously 5 described (16). We subsequently expanded a population of IOSE-80 cells that had passed 6 through crisis to generate the truly immortal, pre-malignant IOSE-80pc line (17). In all 7 experiments performed here, IOSE-80pc cells were maintained in 199:105 medium (1:1; Sigma, 8
St. Louis MO) supplemented with 5% Fetal Bovine Serum (Invitrogen, Carlsbad CA) and 50 9 μg/ml gentamycin (Sigma). For monolayer culture, cells were plated on regular tissue culture 10 plates at sub-confluent densities (5 X 10 4 cells/cm 2 ). For suspension culture, tissue culture plates 11 were pre-coated with 5mg/ml of non-adhesive poly[2-hydroxyethyl methacrylate] (polyHEMA, 12
Sigma; Ref. 18) and cells were plated at the density described above. Under the latter conditions 13 the cells did not attach to the dish. Instead, they floated in suspension and, given the relatively 14 high density of plating, aggregated and formed small rounded clusters (see Results section, 15 below). Conditioned medium, generated when cells were maintained in either monolayer or 16 suspension culture, was cleared of cells by centrifugation (200 Xg, 5 minutes) and added to 17 cultures immediately. Live, phase images of monolayer and suspension cultures were collected 18 using a Nikon TMS phase microscope. 19 20
Real-time quantitative PCR 21
Total RNA was extracted from IOSE-80pc cells maintained in either monolayer or 22 suspension culture. cDNA was then synthesized using a high-capacity cDNA archive kit 23 (Applied Biosystems, Foster City, CA) and real-time PCR analysis was performed using 20 ng 24 Zhou et al.
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of template in 15ul reactions containing Taqman universal PCR master mix as well as BRCA1 1 primers and probe (HS00173237; Applied Biosystems, Burlington ON, Canada). 18s rRNA was 2 simultaneously quantified as the internal control. Amplification was performed in an ABI prism 3 7500 HT sequence detector using standard settings of 40 cycles with an annealing temperature of 4 60 o C. All samples were assayed in 3 parallel reactions, and three independent experiments were 5 performed with similar results. The L6 proximal promoter region of BRCA1 was excised from the L6-pRL construct (7) 19 with BglII and HindIII and ligated directly into the pGL4.11 (Luc2P, Promega, Madison WI) 20 basic, minimal promoter vector containing the firefly luciferase reporter. To generate the BRCA1 21 promoter mutants used here, the respective DNA strands were synthesized, annealed, and ligated 22 into pGL4.11 as previously described (7, 19) . For the PRR construct two synthetic primers 23 on June 24, 2017. © 2013 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on January 21, 2013; DOI: 10.1158/1541-7786.MCR-12-0395 ( 5'GATCTTTCTTCCTCTTCCGTCTCTTTCCTTTTACGTCATCCGGGGGCAGACA -3'and 1 5'AGCTTGTCTGCCCCCGGATGACGTAAAAGGAAAGAGACGGAAGAG 2 GAAGAAA -3') were designed to include the BRCA1 promoter region from -201 to-155 and to 3 contain adapters of the BglII and HindIII enzymes for annealing and ligation. The 'RIBSm' 4 (previously described as 'CREs') and 'CREm' mutants shown (see Fig 2) were then generated by 5 site-directed mutagenesis as previously described (6,7). All promoter/reporter constructs were 6 confirmed by sequencing. test statistical analyses were performed using GraphPad Prism6 (GraphPad, La Jolla, CA). A p 1 value of less than 0.05 was considered statistically significant. 2 c-Jun-and Fra2-specific, as well as random control, small interfering RNAs (siRNAs) 3 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Cell monolayers were 4 transfected with siRNAs using lipofectamine RNAiMAX (Life Technologies) with a total of 5 25nM siRNA (12.5nM c-Jun siRNA plus 12.5nM Fra2 siRNA; or 25nM total of random 6 siRNAs). After 24 h, cells were dissociated and were then maintained in either monolayer or 7 suspension culture for a further 48 h prior to analysis by Western blotting. 8 9 Western Blotting 10 Cells were lysed, on ice, in RIPA buffer (159mM NaCl, 50mM Tris-HCL, ph7.5, 1% NP-11 40, 1% deoxycholate, 0.1% SDS, 2mM EDTA, plus 1 μM pepstatin, 10 μg/ml aprotinin, 10mM 12 PMSF, and 2 μg/ml leupepin), sonicated to generate whole cell lysates, cleared by centrifugation, 13 and protein was quantified by BCA TM protein assay kit (Pierce, Rockford, IL). 20 μg of whole 14 cell lysate protein was size-fractioned on 7% SDS-PAGE gels to detect BRCA1 or 12% SDS-15 PAGE gels to detect c-Jun, Fra2, A-Fos and ERK1/2. Gels were blotted overnight onto PVDF 16 membranes (Bio-RAD, Hercules, CA) which were then blocked with 5% skim milk and 17 incubated with the primary antibodies indicated followed by incubation with the appropriate 18 species-specific peroxidase-labelled second antibody. Antibody binding was then visualized by 19 enhanced chemiluminescence (Amersham Life Science, Buckinghamshire, England). After first 20 establishing that there steady state levels were not altered by changing the culture conditions (see 21 
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Cell monolayers were transfected with His-tagged c-Jun and Fra2 expression vectors, 1 maintained for 48 h, fixed in cold methanol, and immunostained with antibodies against the His-2 tag of the transgenes. Nuclei were counterstained with 4',6-diamidino-2-phenylindole (DAPI, 3 Sigma) and images were collected using an Olympus FV100 confocal microscope. Nuclear extracts from cells maintained either as flat monolayers or as clusters in 7 suspension for 48 hr were prepared as previously described (6), with the exception that nuclear 8 proteins were not concentrated by (NH 3 ) 2 SO 4 precipitation, but instead were dialyzed against 10 9 mM HEPES pH 7.6, 40 mM KCl, 0.1 mM EDTA, and 10% glycerol. Nuclear extracts were then 10 combined with 32 P-labelled BRCREO oligonucleotide plus strand 5'-11 CTTTCCTTTTACGTCATCCGGGGGCAGACT-3' minus strand 5'-12 AGTCTGCCCCCGGATGACGTAAAAGG-3' or with CREOmut 5'-13
CTTTCCTTTTAatTCATCCGGGGGCAGACT-3' minus strand 5'-14 Zhou et al.
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Results 1
BRCA1 expression is suppressed in premalignant OSC cells maintained in suspension 2
culture. 3
Human OSE cells, which are mesodermally-derived, do not express E-cadherin. Thus, 4 OSE cells tend to become fibroblastic when they are explanted into monolayer culture (17). 5
Cells of the immortal, pre-malignant IOSE-80pc line took on this fibroblastic appearance when 6 they were maintained as monolayers on tissue culture plastic ( Fig 1A 'Mono') . In contrast, when 7 IOSE-80pc cells were maintained in suspension they rounded-up and formed loosely adherent 8 clusters of cells ( Fig 1A, ' Susp') that are not dissimilar in appearance to the clusters that ovarian 9 carcinoma cells form after they have been shed into the adominopelvic cavity during the initial 10 stages of transperitoneal spread (24). Interestingly, steady-state BRCA1 mRNA and protein 11 levels were both reduced considerably when the cells were maintained in suspension culture ( To determine if soluble factors released by IOSE-80pc cells contribute to the differences 14 in BRCA1 expression described above we cultured them in media pre-conditioned by cells in 15 either monolayer or suspension culture. Clearly, this pre-conditioned media had little or no effect 16 on BRCA1 levels ( Fig 1D) . Therefore, it is unlikely that soluble factors contributed to the 17 suppression of BRCA1 expression that occurred in suspension culture. This tentative conclusion 18 was supported by the observation that the reduction in BRCA1 expression due to suspension 19 culture was reversed when suspension cells were replated as monolayers using the same 20 suspension medium ( Fig 1E) . The latter finding also indicates that the suppression of BRCA1 21 expression initiated in suspension culture was reversible. Transactivation of a positive regulatory region (PRR) within the BRCA1 promoter is 1 suppressed in suspension culture. 2
As the steady state levels of BRCA1 mRNA as well as protein were suppressed in IOSE-3 80pc cells maintained in suspension, we next assessed the effect of this culture condition on the 4 transactivation state of the BRCA1 promoter. 5
The BRCA1 promoter, which acts bidirectionally, is located on the long arm of 6 chromosome 17 between the NBR2 and BRCA1 genes (Fig 2A) . Previously, we determined that 7 a 231 bp form of the promoter (i.e. the 'L6' promoter, -204nt to +27nt) contains a very strong 8 'positive regulatory region' (i.e. the PRR fragment, -204nt to -155nt) that is maximally active in 9 both ovarian carcinoma and IOSE cells (3). Importantly, the ability of both the L6 promoter and 10 the PRR fragment to transactivate and drive reporter gene expression was reduced when IOSE-11 80 cells were maintained in suspension culture compared to when they were maintained in 12 monolayer culture ( Fig 2B) . While the suspension culture-mediated suppression of the entire L6 13 promoter was a trend, the decrease in the PRR was larger (ie. approximately three fold) and 14 statistically significant. 15
The PRR fragment contains two positively-acting binding elements; the upstream RIBS 16 element and the downstream CRE element (Fig 2A) . When the upstream 'RIBS' element was 17 disrupted by mutation (i.e. 'RIBSm' in Fig 2A) , the PRR activity fell significantly in monolayer 18 culture. However, the activity of this mutant, which had a wild type CRE-element, was further 19 reduced in the suspension culture ( Fig 2B) . In contrast, when the downstream CRE binding 20 element was mutated (i.e. 'CREm' in Fig 2A) , PRR activity was also greatly decreased in 21 monolayer culture, but there was no further decrease in suspension culture ( Fig 2B) . These data Previously, we determined that the RIBS element helps to activate the PRR fragment of 4 the BRCA1 promoter by binding GABPα and GABPß transcription factor subunits in breast and 5 ovarian carcinoma cells in standard monolayer culture conditions. In contrast, the CRE element 6 contributes to PRR activation by binding c-Jun and Fra2 members of the AP1 transcription factor 7 complex in standard monolayer conditions (3,6,7). As such, we carried out chromatin 8 immunoprecipitation (ChIP) assays and confirmed that GABPα ('Alpha'), c-Jun, and Fra2 all 9 bound PRR-containing chromatin in IOSE-80pc cell monolayers ( Fig 3A) . We were unable to 10 assess GABPß binding in this assay given that, in our hands, the commercially available 11 antibody we utilized for Western blotting (see below) did not efficiently immunoprecipitate 12
chromatin. 13
We next assessed the steady state levels of GABPα, GABPß, c-Jun, and Fra2 proteins in 14 IOSE-80pc cells maintained in the two different culture conditions. There was no decrease in the 15 level of either GABPa or GABP/ß in suspension culture ( Fig 3B) . This observation, and the 16 observation described above which indicated that mutating the GABPa/ß-binding RIBS element 17 (6) did not abrogate suspension-mediated suppression of the PRR, led us to conclude that 18 changes in the levels of these factors are not likely critical regulators of this phenomenon. In 19 contrast, the steady state levels of c-Jun and Fra2 were both reduced in suspension culture (Fig  20   3C ). This finding, and the finding described above which indicated that mutating the c-Jun/Fra2-21 binding CRE element (7) abrogated suspension-mediated suppression of the PRR led us to 22 tentatively conclude that the decrease in these factors may contribute to the suppression of 23 BRCA1. This notion was supported by the data generated by electrophoretic mobility shift 24 assays using the CRE as probe. Specifically, supershifting with antibodies that recognized c-Jun 1 and Fra2 indicated that complexes formed from nuclear extracts of cells maintained in 2 monolayer culture and that these complexes were reduced when the cells were maintained in 3 suspension ( Fig 3D) . Given these findings, and the changes in promoter activity, we decided to 4 next determine if manipulating c-Jun/Fra2 levels affected the suspension culture-mediated 5 suppression of BRCA1 promoter activity. To test the effects of c-Jun and Fra2 specifically, we force expressed both transcription 16 factors together, by dual transfection. In standard monolayer culture conditions, this greatly 17 increased the activation of the L6 promoter and the wildtype form of the PRR fragment ( Fig 4A) . 18
Forced expression of c-Jun and Fra2 also increased the activation of the RIBS mutant, but not the 19 CRE mutant, of the PRR (Fig 4A) . The latter result was expected given the fact that the former, 20 but not the latter, still has an intact AP1-binding site for c-Jun and Fra2 (3,7). Importantly, 21 however, the same pattern of increased activation of the L6 promoter, the wtPRR region, and the 22 PRR/RIBS mutant, but not the PRR/CRE mutant, also occurred when the cells were maintained 23 in suspension ( Fig 4B) . This further supports the notion that the decrease in endogenous c-Jun 1 and Fra2 levels that occurs in suspension culture may contribute to BRCA1 suppression. 2
We next assessed the effect of forced c-Jun and Fra2 on IOSE-80pc cell proliferation. In 3 general, the cell spreading that occurs in monolayer culture faciliates proliferative growth factor 4 signaling, a phenomenom that is curtailed as cells round and are released into suspension (25). 5 IOSE-80pc cells fit this paradigm. Specifically, IOSE-80pc proliferation fell significantly when 6 the cells were switched from being flat and spread in monolayer culture to rounded and clustered 7 in suspension culture ( Fig 5) . Importantly, while forced c-Jun/Fra2 expression increased 8 proliferation modestly in both the monolayer and suspension culture conditions, the total 9 percentage of proliferating cells remained much lower in the suspension condition. Therefore, 10 the ability of forced c-Jun/Fra2 expression to robustly stimulate BRCA1 promoter transactivation 11 in suspension culture was not likely caused by a general ability to stimulate proliferation back to 12 the levels observed in monolayer culture. 13 14
c-Jun and Fra2 regulate endogenous BRCA1 levels in monolayer and suspension culture 15
When we force-expressed wild type c-Jun and Fra2 in IOSE-80pc cells by co-16 transfection, the exogenous forms of the transcription factors were identified by Western blotting 17 for the epitope tag (Fig 6A, anti-His-tag blots) , and the overall increase for each could be 18 observed by blotting specifically for either c-Jun or Fra2 in both monolayer and suspension 19 culture (Fig 6A, anti-c-Jun and Fra2 blots). This forced c-Jun/Fra2 expression increased 20 endogeneous BRCA1 protein levels modestly in monolayer cultures and strongly in suspension 21 cultures ( Fig 6A) . 22
To confirm that changes in c-Jun and Fra2 levels alter BRCA1 expression in both 23 monolayer and suspension culture, we also knocked both transcription factors down coordinately 24 using siRNA-mediated co-transfection ( Fig 6B) . In response to this coordinated knockdown, 1 BRCA1 protein levels were greatly reduced when the cells were maintained in monolayer culture 2 and there was a further reduction in the already suppressed BRCA1 level when the cells were 3 maintained in suspension culture ( Fig 6B) . Therefore, we concluded that the decrease in 4 endogenous c-Jun and Fra2 levels that occurs when IOSE-80pc cells are maintained in 5 suspension culture contributes to the resultant suppression of BRCA1. Ovarian carcinoma, which consists of a number of histologically distinct subtypes, is 2 unusual in that it often spreads transperitoneally (26). During this process tumor cells are first 3 shed from the primary lesion and they float freely, often as small clusters, within the peritoneal 4 fluid of the abdominopelvic cavity (27) . It is these floating tumor cell clusters that, if they 5 subsequently adhere to peritoneal surfaces at sites distant from the primary lesion, can expand 6 and become locally invasive. This process is particularly prominent in the high grade serous 7 tumors which are shed early in their progression and go on to form the most prominent and lethal 8 ovarian carcinoma subtype by far (28). High grade serous ovarian carcinoma tumors are also 9 notable in that they often exhibit BRCA1 abnormalities, only a small percentage of which are 10 caused by genetic mutation. Thus, epigenetic suppression is a major factor in the histogenesis of 11 these tumors (2). 12
The tumor microenvironment is known to regulate BRCA1 expression. This has been 13 best studied in the breast where the extracellular matrix, hormones and hypoxia have all been 14 shown to alter BRCA1 levels by impinging on the gene's transcriptional and post-translational 15 regulation (13, 14, 22, 29, 30) . Given that release from the extracellular matrix is a major 16 microenvironmental change that occurs as ovarian carcinoma begins to disseminate by floating 17 as effusive tumor cell clusters in the fluid of the peritoneal cavity (27) and the fact that BRCA1 18 levels are reduced in disseminated high grade serous tumour cells compared to their tissue of 19 origin (31), we released pre-malignant ovarian cells from the ECM, maintained them as clusters 20 in suspension culture, and determined the effect on BRCA1 levels. Under suspension conditions, 21 BRCA1 levels were decreased considerably and this decrease was mediated, at least in part, 22
transcriptionally. More specifically, we demonstrated that a suspension-mediated decrease in the 23 AP1 transcription factor components c-Jun and Fra2 contributed to inhibition of BRCA1 24 on June 24, 2017. © 2013 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on January 21, 2013; DOI: 10.1158/1541-7786.MCR-12-0395 promoter transactivation and endogenous BRCA1 gene expression. At this point we cannot state 1 definitively that GABPa and GABPß, two ETS-like transcription factors that also positively 2 regulate the BRCA1 promoter are not involved in this suppression. However, it was clear that 3 releasing the cells into suspension did not affect the steady state levels of either GABP factor 4 which is why we focussed on c-Jun and Fra2 for the remainder of this initial study. It is also 5 important to note that other, as yet unidentified factors, may be involved in the BRCA1 6 suppression given the large decrease in wild type PRR activation we observed in suspension 7 culture that we could not fully recapitulate in either of the RIBS or CRE element mutants. 8
Cells in monolayer culture have engaged integrins and, because they are spread on a rigid 9 tissue culture substratum, their cytoskeletal tension is high, both of which contribute to the 10 mechanical augmentation of growth factor-mediated signaling that leads to the expression of 11 various factors, including components of the AP1 transcription factor complex (32,33). At this 12 point it is not clear if a loss of integrin signaling or a decrease in cytoskeletal tension, or both, 13 contributed to the decrease in c-Jun and Fra2 when IOSE-80pc cells were maintained as rounded 14 cell clusters in suspension. However, this decrease also occurred when the cells were clustered 15 and maintained on compliant reconstituted basement membrane gels where integrins were 16 engaged but the cells remained rounded (data not shown). One way to address this issue 17 definitively would be to alter the rigidity of the substratum after the cells are already attached 18 such that cytoskeleton tension is modulated while the integrins are continuously engaged with 19 the extracellular matrix. These are experiments that we are currently attempting by coating 20 silicone rubber ECM substrata that can then be stretched to increase its rigidity after cells are 21 pre-attached. It will also be interesting to determine if the suspension-mediated decrease in c-Jun 22
and Fra2 affect other aspects of the ovarian carcinoma phenotype, although at this point we have 23 not noticed that there is any change in adhesion or invasiveness (eg. on basement membrane 1 gels). 2
The BRCA1 promoter constitutes a large CpG island that is hypermethylated in up to 3 30% of spontaneous ovarian epithelial carcinomas (34, 35) . Importantly, this hypermethylation is 4 associated with decreased BRCA1 expression and poor clinical outcome (36). One of the CpG 5 targets for methylation in the BRCA1 promoter is the CRE element (37). In fact, the 'CREm' 6 mutation used in this study that eliminated the differential monolayer-and suspension culture-7 mediated activation and prevented c-Jun/ Fra2 binding, removes the major hypermethylation site 8 within this element. Thus, the decreased binding of c-Jun/Fra2 at this site in suspension culture 9 and, presumably, during shedding into the abdominopelvic fluid in vivo, could, potentially, be a 10 form of initial 'flexible' transcriptional suppression that subsequently helps to facilitate a 'stable' 11 suppression by methylation (38, 39) . If this turns out to be the case, it would mean that the 12 process of tumor cell shedding that is an early hallmark of the deadly transperitoneal spread of 13 high grade serous tumors may help initiate the stable epigenetic suppression of BRCA1 that is 14 prominent in the sporadic form of these tumors. B: Quantitative RT-PCR indicated that steady-state BRCA1 mRNA levels were reduced in cells 7 maintained suspension culture compared to monolayer culture. 8 C: Western blotting indicated that steady-state BRCA1 protein levels were reduced in cells 9 maintained suspension culture; ERK 1/2 levels remained unchanged and therefore were used 10 as loading controls for all subsequent Western blotting in this study. 11 D: Cells maintained in either monolayer or suspension culture conditions ('Culture') were 12 incubated in media previously conditioned by cells maintained either in suspension or in 13 monolayers ('Media') and BRCA1 protein levels were assessed by Western blotting. Note 14 that conditioned media did not appreciably alter BRCA1 levels of cells in either monolayer 15 or suspension culture conditions. 16 E: Cells were maintained in suspension culture for 48 hr and one half of the cells were then 17 lysed; the remaining cells were replated as monolayers for a further 48 hr and lysed. Both 18 lysates were then subjected to Western blotting. Note that the suppression of BRCA1 was 19 reversed when the cells were replated in monolayer culture. 20 Note that approximately 50% of the cells were positive for the epitope-tagged transgenes. 16 B: Cells co-transfected with either empty expression vector constructs or with expression 17 constructs containing c-Jun and Fra2 were maintained in monolayer or suspension culture. 18
Proliferative activity was then assessed by the ability of cells to take up fluorescent EdU (see 19 methods and materials for details). Note that while maintainence in suspension greatly 20 decreased proliferative rates, there was only a slight increase in the percentage of EdU 21 positive cells in either monolayer or suspension culture after co-transfection with c-Jun/Fra2 22 compared to vector control transfectants. 23 24 on June 24, 2017. © 2013 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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